Cluster of Excellence Precision Medicine in Chronic Inflammation (PMI)

Researchers at the FZB have defined the areas in which the development of resistance to two important tuberculosis drugs is favored.

A specific intestinal bacterium produces sphingolipids, via an alternative metabolic pathway, that provide host protection against infection. 
 

The new Research Training Group GRK3095 will investigate the mechanisms by which antibodies trigger either protective or disease-causing responses in the skin, lungs, and gut.

Immunologist from the Cluster of Excellence PMI receives prestigious European Research Council grant for work on regulatory T cells.